Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Cardiology
•
Preventive Cardiology
Should colchicine be considered in patients with ischemic heart disease and persistently elevated hsCRP despite statin and aspirin therapy and appropriate physical activity?
Related Questions
How would you approach the risk-benefit ratio of systemic anticoagulation in certain clinical scenarios such as atrial fibrillation or LV thrombus when a patient's history is also notable for type B aortic dissection or other aortic pathology such as aortic ulceration?
How often do you recommend performing an advanced lipid panel for monitoring of lipid lowering therapy?
How do you counsel patients with metabolic syndrome who decline statin therapy and have low coronary calcium scores regarding their long-term CVD risk?
Would the diagnostic yield for ABIs or peripheral arterial duplex doppler in a patient with metal rods in both legs be similar or acceptable in comparison to those tests in a patient without metal rods?
What are your preferred methods for QTc calculation for normal, tachycardic and bradycardic heart rates?
What are some practical ways to incorporate cardiac POCUS in the primary care setting?
Do you start a statin concurrently with icosapent ethyl for patients with moderate hypertriglyceridemia and high ASCVD risk, or do you prefer to start a statin alone and monitor triglyceride levels?
How would you approach the management of a patient who develops an accelerated junctional rhythm who exhibits no symptoms and has no prior history of cardiac issues, aside from consulting a cardiologist?
When would you consider referring a patient with suspected cardiac sarcoidosis based on PET and MRI for endomyocardial biopsy given degree of patchy involvement, as opposed to initiating empiric immunosuppressive therapies?
Do you pursue a cardiac evaluation in all patients with an excised cutaneous myxoma?
